Raymond James & Associates Abb Vie Inc. Transaction History

Raymond James & Associates

$146 Billion
Q1 2024

A detailed history of Raymond James & Associates transactions in Abb Vie Inc. stock. As of the latest transaction made, Raymond James & Associates holds 4,321,396 shares of ABBV stock, worth $738 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares

4,321,396

Previous 4,509,372 4.17%

Holding current value

$738 Million

Previous $699 Million 12.61%

% of portfolio

0.54%

Previous 0.53%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$159.82 - $182.1 $30 Million - $34.2 Million	-187,976 Reduced 4.17%	4,321,396 $787 Million
Q4 2023 Jan 16, 2024	BUY	$137.6 - $154.97 $10.9 Million - $12.2 Million	79,019 Added 1.78%	4,509,372 $699 Million
Q3 2023 Oct 24, 2023	BUY	$133.59 - $154.65 $12.3 Million - $14.3 Million	92,342 Added 2.13%	4,430,353 $660 Million
Q2 2023 Jul 25, 2023	SELL	$132.51 - $164.9 $41 Million - $51.1 Million	-309,586 Reduced 6.66%	4,338,011 $584 Million
Q1 2023 Apr 14, 2023	BUY	$144.61 - $166.54 $22.9 Million - $26.3 Million	158,105 Added 3.52%	4,647,597 $741 Million

Q4 2022 Feb 08, 2023	BUY	$138.31 - $165.87 $72.6 Million - $87.1 Million	525,233 Added 13.25%	4,489,492 $726 Million
Q3 2022 Oct 25, 2022	BUY	$134.21 - $153.93 $22.9 Million - $26.3 Million	170,536 Added 4.5%	3,964,259 $532 Million
Q2 2022 Aug 12, 2022	SELL	$137.62 - $174.96 $48.2 Million - $61.3 Million	-350,530 Reduced 8.46%	3,793,723 $581 Million
Q1 2022 May 11, 2022	BUY	$131.98 - $163.75 $12.6 Million - $15.6 Million	95,362 Added 2.36%	4,144,253 $672 Million
Q4 2021 Feb 08, 2022	BUY	$107.43 - $135.93 $9.53 Million - $12.1 Million	88,704 Added 2.24%	4,048,891 $548 Million
Q3 2021 Nov 02, 2021	BUY	$106.4 - $120.78 $23.1 Million - $26.2 Million	217,112 Added 5.8%	3,960,187 $427 Million
Q2 2021 Aug 11, 2021	BUY	$105.21 - $117.21 $17.1 Million - $19.1 Million	162,640 Added 4.54%	3,743,075 $422 Million
Q1 2021 May 14, 2021	SELL	$102.3 - $112.62 $1.83 Million - $2.01 Million	-17,866 Reduced 0.5%	3,580,435 $387 Million
Q4 2020 Feb 12, 2021	BUY	$80.49 - $108.67 $28.9 Million - $39 Million	359,157 Added 11.09%	3,598,301 $386 Million
Q3 2020 Nov 04, 2020	SELL	$85.91 - $100.83 $4.71 Million - $5.53 Million	-54,852 Reduced 1.67%	3,239,144 $284 Million
Q2 2020 Jul 28, 2020	BUY	$73.37 - $98.18 $7.5 Million - $10 Million	102,200 Added 3.2%	3,293,996 $323 Million
Q1 2020 Apr 21, 2020	BUY	$64.5 - $97.79 $1.78 Million - $2.7 Million	27,560 Added 0.87%	3,191,796 $243 Million
Q4 2019 Feb 12, 2020	BUY	$72.13 - $90.25 $8.3 Million - $10.4 Million	115,011 Added 3.77%	3,164,236 $280 Million
Q3 2019 Nov 07, 2019	BUY	$62.98 - $75.72 $23.3 Million - $28 Million	369,192 Added 13.78%	3,049,225 $231 Million
Q2 2019 Aug 06, 2019	SELL	$65.7 - $83.98 $112 Million - $143 Million	-1,703,375 Reduced 38.86%	2,680,033 $195 Million
Q1 2019 May 06, 2019	BUY	$77.14 - $90.79 $29 Million - $34.1 Million	375,464 Added 9.37%	4,383,408 $353 Million
Q4 2018 Feb 11, 2019	BUY	$77.85 - $96.01 $36.8 Million - $45.4 Million	472,550 Added 13.37%	4,007,944 $369 Million
Q3 2018 Nov 14, 2018	BUY	$88.91 - $98.84 $11.9 Million - $13.3 Million	134,234 Added 3.95%	3,535,394 $334 Million
Q2 2018 Aug 14, 2018	BUY	$89.78 - $106.23 $9.72 Million - $11.5 Million	108,230 Added 3.29%	3,401,160 $315 Million
Q1 2018 May 14, 2018	SELL	$92.01 - $123.21 $57.1 Million - $76.4 Million	-620,233 Reduced 15.85%	3,292,930 $312 Million
Q4 2017 Feb 14, 2018	SELL	$89.56 - $98.21 $47.5 Million - $52 Million	-529,915 Reduced 11.93%	3,913,163 $378 Million
Q3 2017 Nov 13, 2017	SELL	$69.85 - $89.22 $52.4 Million - $66.9 Million	-750,093 Reduced 14.44%	4,443,078 $395 Million
Q2 2017 Aug 14, 2017	BUY	N/A	5,193,171	5,193,171 $377 Million

Others Institutions Holding ABBV

# of Institutions

3,650

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $302B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Abb Vie Inc. Transaction History